PetMed Express, Inc. Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2023. The filing also presents fourth-quarter results for the three months ended March 31, 2023; the requested “2022 Q4” period does not match the filing’s stated reporting period.
Business Context
PetMed Express, Inc., doing business as PetMeds, is a direct-to-consumer pet pharmacy and online retailer offering prescription and non-prescription medications, food, supplements, supplies, telemedicine and related services for dogs, cats and horses. Sales are generated primarily through its websites and mobile applications, with additional sales through its call center.
- Approximately 86.4% of fiscal 2023 sales were generated through Internet channels.
- Approximately 44.4% of fourth-quarter fiscal 2023 sales were generated through the AutoShip subscription program.
- The Company acquired PetCareRx on April 3, 2023, after fiscal year-end, for approximately $36.0 million in cash.
Financial Results and Key Metrics
| Metric | Fiscal 2023 | Fiscal 2022 | Change |
|---|---|---|---|
| Net sales | $256.9 million | $273.4 million | Down 6.1% |
| Gross profit | $71.0 million | $78.1 million | Down 9.0% |
| Gross margin | 27.6% | 28.6% | Down 100 basis points |
| Operating income | $(1.4) million | $25.7 million | Declined materially |
| Net income | $0.2 million | $21.1 million | Down 98.9% |
| Diluted earnings per share | $0.01 | $1.04 | Down $1.03 |
| Adjusted EBITDA | $19.8 million | $34.0 million | Down 42% |
| Cash flow from operations | $27.8 million | $18.5 million | Up $9.3 million |
Fiscal 2023 operating expenses increased substantially. General and administrative expense rose 60.5% to $49.5 million, including a $7.8 million sales-tax accrual, $1.9 million of acquisition-related expenses, higher professional fees, increased software costs, severance and stock compensation. Advertising expense increased to $19.4 million, or 7.6% of sales.
At March 31, 2023, cash and cash equivalents were $104.1 million, working capital was approximately $95.0 million, and total liabilities were $40.3 million. The Company reported no debt obligations. Inventory declined to $19.0 million from $32.5 million, while accrued expenses and other current liabilities increased to $11.3 million from $5.7 million, primarily reflecting accrued sales tax.
Fiscal 2023 investing cash outflows were $10.3 million, including a $5.0 million investment in Vetster and $5.3 million of property and equipment purchases. Financing cash outflows were $24.5 million, primarily quarterly dividends. The Company declared $1.20 per common share in dividends for fiscal 2023 and had approximately $28.7 million remaining under its share repurchase authorization; no shares were repurchased during fiscal 2023.
Material Changes Versus the Prior Comparable Period
- Sales declined 6.1%, reflecting higher customer acquisition costs, competitive pressure and a crowded, more expensive advertising market.
- New customers declined to approximately 274,000 from approximately 325,000. Advertising cost per new customer increased to $71 from $58.
- Reorder sales declined 4.9%, while new-order sales declined 16.2%.
- Cost of sales decreased in dollars but increased to 72.4% of sales from 71.4%, primarily due to higher per-order freight expense.
- Gross margin fell to 27.6% from 28.6%.
- Operating results shifted from $25.7 million of operating income to a $1.4 million operating loss.
- Net income fell to $0.2 million from $21.1 million, while the effective tax rate increased to 85.3% from 22.1%, partly because of non-deductible acquisition costs, restricted stock compensation and expanded state tax filing requirements.
- AutoShip penetration improved to 44.4% of fourth-quarter sales from 30.9% in the comparable prior-year quarter.
Guidance, Outlook, Risks and Unusual Items
- Management set a goal of approximately 50% of PetMeds net sales through AutoShip in fiscal 2024.
- Management expects fiscal 2024 general and administrative expense to approximate 17% of sales, stock compensation expense to approximate $6.4 million, and advertising expense to approximate 8% of sales.
- The PetCareRx acquisition is expected to expand the product catalog, add approximately 286,000 customers and increase exposure to premium food, supplements, treats and other supplies. Post-acquisition integration, licensing and operating risks remain material.
- The Company recorded a $7.8 million accrual for potential state sales-tax exposure following an assessment and review of jurisdictions under the Wayfair decision. The filing does not provide a final resolution or definitive total liability.
- The Company entered into a three-year exclusive telehealth partnership with Vetster and invested $5.0 million for an approximately 5% minority interest. The investment was not impaired at March 31, 2023.
- The Company expects to offer co-branded pet insurance products with Pumpkin during fiscal 2024, subject to insurance licensing and regulatory requirements.
- Key risks include regulatory or pharmacy-license actions, competition from veterinarians and retailers, supplier concentration, inventory and shipping disruptions, cybersecurity and data privacy incidents, dependence on digital systems, economic pressure on consumer spending, seasonality and acquisition integration.
- Management and the auditors identified a material weakness in internal control over financial reporting involving inadequate segregation of duties over preparation, approval and posting of manual journal entries. Management stated that the weakness did not result in a material misstatement and is developing a remediation plan.
- Routine litigation and administrative complaints are disclosed, including pharmacy-related matters; management does not believe they are reasonably likely to have a material adverse effect, but outcomes remain uncertain.
Investor Verification Items
- Verify the scope, collectability and ultimate resolution of the $7.8 million state sales-tax accrual.
- Assess whether PetCareRx integration delivers expected customer, catalog and revenue benefits and whether additional cash requirements arise.
- Monitor remediation of the material weakness and future auditor assessments of internal controls.
- Evaluate whether sales, customer acquisition costs and gross margin stabilize amid heightened competition and advertising inflation.
- Review the sustainability of quarterly $0.30 per-share dividends in light of reduced profitability, the PetCareRx acquisition and other strategic investments.
- Assess the performance and impairment risk of the Vetster investment and the commercial adoption of telehealth and planned pet-insurance offerings.